A telehealth company is selling the Ozempic class of drugs for addiction. The evidence is thin.

Quel Health launched on Tuesday as a telehealth company built around prescribing GLP-1 receptor agonists for substance use disorders, according to a PRWeb announcement covered same-day by STAT News. The pitch routes a drug class developed for Type 2 diabetes and obesity, the same class as Ozempic, Wegovy, and Mounjaro, into alcohol use disorder, opioid use disorder, and what the company describes as behavioral addictions.

GLP-1 agonists work on receptors in the gut and brain that modulate appetite, glucose, and reward processing. The neural circuitry that drives food craving overlaps with the circuitry implicated in alcohol and opioid craving, which is the scientific bet behind testing these drugs for addiction. That bet now has its first major trial result: a semaglutide-versus-placebo study in patients with AUD and comorbid obesity published in The Lancet in 2026 by Klausen et al.00305-3/fulltext).

A second trial, Hendershot et al. in JAMA Psychiatry in 2025 (NCT05520775), tested once-weekly semaglutide in patients with AUD and reported signals on drinking reduction. Both trials enrolled participants with comorbid obesity or metabolic risk, so they speak to a slice of the AUD population rather than the whole.

The Science Media Centre's expert reaction roundup to the Klausen paper, published April 30, 2026, gathered independent clinician commentary. Clinicians in the roundup were cautious: the AUD evidence base is one large trial plus smaller studies, with limited data in patients without comorbid metabolic disease, and no RCT evidence yet for opioid, stimulant, or behavioral addictions.

Outside academia, established treatment providers are already positioning around the indication. Caron Treatment Centers publicly frames itself as a leader in GLP-1 innovation for addiction, a signal that the metabolic-to-behavioral pipeline has institutional traction beyond a single launch.

Three questions follow Quel Health's debut. What specifically is the company prescribing, for which substance use disorders, and how does it handle screening, lab work, and continuity of care without an in-person visit? Independent evidence for opioid use disorder, stimulant use disorder, and behavioral addictions is observational or absent, so the indication list on the company's website extends well beyond the published trial base. And the FDA has not approved any GLP-1 agonist for an addiction indication, so every prescription is off-label.

The launch puts one question to the channel itself: whether a fully remote clinic can credibly host injectable pharmacotherapy for a population that often needs screening for pancreatitis, gallbladder disease, and suicidal ideation, and where continuity of care during relapse is part of the standard of care. Quel Health's PRWeb release describes a clinical model; the published trial base describes a narrower one. The next twelve months of prescriptions will start to close the gap between them.